US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

24.62

-0.9500-3.72%

Volume:684.39K

Turnover:17.19M

Market Cap:1.41B

PE:-9.51

High:26.90

Open:26.38

Low:24.30

Close:25.57

Loading ...

Overview Company News Filings

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets

William Blair Initiates Structure Therapeutics at Outperform

MT Newswires Live

Structure Therapeutics Initiated at Outperform by William Blair

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Structure Therapeutics Inc. FY Net Income USD -122.526 Million

THOMSON REUTERS

Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027

THOMSON REUTERS

Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million

THOMSON REUTERS

Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement

MT Newswires Live

Exicure announces purchase agreement with GPCR Therapeutics

Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Structure Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $50

THOMSON REUTERS

Structure Therapeutics initiated with a Buy at Stifel

Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

BUZZ-Viking set to double in 'challenging' year for obesity drug developers

Exicure to Acquire GPCR Therapeutics' US Unit

MT Newswires Live

Exicure signs MOU with GPCR Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GPCR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":24.62,"timestamp":1747080000000,"preClose":25.57,"halted":0,"volume":684394,"delay":0,"floatShares":49646003,"shares":57342847,"eps":-2.590061,"marketStatus":"Pre-Mkt","change":-0.95,"latestTime":"05-13 04:55:17 EDT","open":26.38,"high":26.9,"low":24.295,"amount":17192280.466542,"amplitude":0.101877,"askPrice":30.93,"askSize":100,"bidPrice":22.23,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.590061,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747143000000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":24.62,"postHourTrading":{"tag":"盘后","latestPrice":24.5129,"preClose":24.62,"latestTime":"18:09 EDT","volume":10513,"amount":259352.1217,"timestamp":1747087763470},"volumeRatio":0.9598252913933654,"impliedVol":0.5171,"impliedVolPercentile":0.0161},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":49646003,"roa":"-17.24%","roe":"-22.85%","lyrEps":-2.327592,"volumeRatio":0.9598252913933654,"shares":57342847,"dividePrice":0,"high":26.9,"amplitude":0.101877,"preClose":25.57,"low":24.295,"week52Low":13.22,"pbRate":"1.71","week52High":62.74,"institutionHeld":0,"latestPrice":24.62,"eps":-2.590061,"divideRate":0,"volume":684394,"delay":0,"ttmEps":-2.590061,"open":26.38,"prevYearClose":27.12,"prevWeekClose":25.57,"prevMonthClose":27,"prevQuarterClose":17.31,"fiveDayClose":27.545,"twentyDayClose":15.9,"sixtyDayClose":24.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516634659","title":"AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634659","media":"Blockhead","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634659?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:04","pubTimestamp":1741014273,"startTime":"0","endTime":"0","summary":"AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/abbvie-stock-weight-loss-drug-gubra-licensing-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["GPCR","LU1974910355.USD","LU1244550221.USD","LU1934455863.HKD","LU2491050154.USD","LU1496350502.SGD","BK4532","LU1868836757.USD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BKVL7J92.USD","IE0002141913.USD","IE0009355771.USD","LU1720051017.SGD","LU2023250504.SGD","LU0203202063.USD","LU1720051108.HKD","LU1839511570.USD","LU1280957306.USD","NVO.AU","LU0006306889.USD","BK4007","BK4581","LU1244550494.USD","LU1804176565.USD","LU2106854487.HKD","SG9999014914.USD","LU1917777945.USD","LU0094547139.USD","LU2361044865.SGD","LU0234570918.USD","IE00B42XCP33.USD","LU2237443549.SGD","LU2133065610.SGD","LU2237443465.HKD","IE00BJJMRZ35.SGD","VKTX","ABBV","LU0820561818.USD","LU0553294199.USD","LU0109391861.USD","LU2324357040.USD","SG9999015945.SGD","BK4139","LU0708994859.HKD","LU1035775433.USD","LU1267930730.SGD"],"gpt_icon":1},{"id":"2516092633","title":"Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516092633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516092633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:08","pubTimestamp":1741007333,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2516379506","title":"Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379506","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379506?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:58","pubTimestamp":1740758280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 10:58 ET (15:58 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2514329134","title":"William Blair Initiates Structure Therapeutics at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329134?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:05","pubTimestamp":1740747928,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) has an average rating of buy and mean price target of $81.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","GPCR"],"gpt_icon":0},{"id":"2514326997","title":"Structure Therapeutics Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326997?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:16","pubTimestamp":1740744960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 07:16 ET (12:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2514318237","title":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318237?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:07","pubTimestamp":1740726458,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp Feb 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Coca-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","ALT","MNST","KO","LU0289960550.SGD","IE00BBT3K403.USD","LU1992135472.HKD","JAMF","LU0175139822.USD","LU2506952097.USD","GPCR","CRBP","IE00B1BXHZ80.USD","BE","BIOA","PSBD","LU0823414478.USD","ARRY","CCOI","ADSK","ICUI","RUN","IOVA","NTLA","LU0106261372.USD","LU1037948541.HKD","SJM","IE00BFTCPJ56.SGD","NUVL","FOLD","ORA","ALHC","TERN","HRL","IE0002141913.USD","STWD","BK4226","CARS","LU0012050646.USD","RLAY","DUOL","TASK","LU0965509010.AUD","NTAP","VAC","RKT","IE00BJJMRZ35.SGD"],"gpt_icon":1},{"id":"2514998330","title":"Structure Therapeutics Inc. FY Net Income USD -122.526 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514998330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514998330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2514355504","title":"Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355504?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2514233054","title":"Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233054?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2514233058","title":"Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233058?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Aleniglipron  ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025. Oral small molecule amylin receptor agonist  Investigational New Drug -enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025. Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million. SAN FRANCISCO, Feb. 27, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ","BK4139","BK4599","BK4007"],"gpt_icon":1},{"id":"2507062300","title":"Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507062300","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507062300?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:30","pubTimestamp":1738243800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Jan. 30, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/structure-therapeutics-participate-multiple-upcoming-133000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","HCSG","LENZ","BK4599","BK4007","GPCR","BK4139"],"gpt_icon":0},{"id":"2505402066","title":"Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505402066","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505402066?lang=en_us&edition=fundamental","pubTime":"2025-01-23 16:52","pubTimestamp":1737622351,"startTime":"0","endTime":"0","summary":"Exicure  said late Wednesday it has agreed to acquire all shares of GPCR Therapeutics USA, a subsidiary of GPCR Therapeutics, a Korean corporation.In connection with the deal, Exicure and GPCR made a licensing and collaboration agreement to further develop and commercialize certain GPCR technologies, the company said.Financial terms were not disclosed.Under the agreement, Exicure is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.Shares of Exicure were up more than 46% in Wednesday's after-hours activity.Price: 15.21, Change: +4.84, Percent Change: +46.67","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","BK4599","GPCR","XCUR"],"gpt_icon":1},{"id":"2505706822","title":"Exicure announces purchase agreement with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706822?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:05","pubTimestamp":1737579939,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) “announced that on January 19, 2025, Exicure Inc. entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","BK4599","XCUR","BK4139","BK4007"],"gpt_icon":0},{"id":"2505705211","title":"Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705211","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705211?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:01","pubTimestamp":1737579660,"startTime":"0","endTime":"0","summary":"Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc.  entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation , pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation . The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR.In December of last year, GPCR USA presented results at the American Society of Hematology conference, indicating that inhibiting both CXCR4 and ADRB2  resulted in a more than tenfold increase in the anti-cancer efficacy of the AML chemotherapy drug cytarabine. Notably, they reported high response rates and excellent safety profiles in patients receiving the new blood cancer drug daratumumab. Dr. Caderelli stated, \"After completing patient treatment, we","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GPCR","HSCT","XCUR","BK4599","BK4160","BK4007","CTO"],"gpt_icon":1},{"id":"2501074060","title":"Structure Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2501074060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501074060?lang=en_us&edition=fundamental","pubTime":"2025-01-08 19:29","pubTimestamp":1736335776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O4193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2501758537","title":"Structure Therapeutics initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2501758537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501758537?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:21","pubTimestamp":1736284876,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of metabolic t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4007","SF","BK4599","LENZ","GPCR","BK4139"],"gpt_icon":0},{"id":"2501238174","title":"Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501238174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501238174?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164800,"startTime":"0","endTime":"0","summary":"Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company's finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar's Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","SEPN","BK4599","TM","03160","GPCR","BK4555","BK4099","BK4588"],"gpt_icon":0},{"id":"2500617073","title":"BUZZ-Viking set to double in 'challenging' year for obesity drug developers","url":"https://stock-news.laohu8.com/highlight/detail?id=2500617073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500617073?lang=en_us&edition=fundamental","pubTime":"2025-01-01 00:58","pubTimestamp":1735664317,"startTime":"0","endTime":"0","summary":"BUZZ-Viking set to double in 'challenging' year for obesity drug developers ** Viking Therapeutics' VKTX.O shares have more than doubled this year, on track for a third successive year of gains** Shares of other smaller obesity drug developers such as Structure Therapeutics GPCR.O, Altimmune ALT.O and Amgen AMGN.O are set to end the year in the red ** BMO Capital analysts termed 2024 a \"challenging year for obesity trade\" - as investors previously got significant returns by banking on names such as VKTX, GPCR and ALT that were entering the weight-loss space** Brokerage says that while obesity remains an \"enormous\" long-term revenue opportunity, investors have become more selective and focus on \"clearly differentiated\" products ** In November, VKTX reported promising data of its oral drug candidate, VK2735, but analysts raised concerns about its ability to mass produce the treatment ** Data from Amgen's closely watched weight-loss drug MariTide failed to impress investors — and wiped of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nL4N3NW0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4007","IE00B2B36J28.USD","LU0058720904.USD","BK4533","BK4581","LU0868494617.USD","GPCR","BK4566","BK4139","ALT","LU2112291526.USD","LU1878469433.USD","BK4534","IE0002141913.USD","VKTX","AMGN","LU2242652126.USD","BK4599","IE00B4R5TH58.HKD","IE0009355771.USD","LU1571399168.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1023059063.AUD","LU2242646821.SGD","SG9999001440.SGD","LU1983299246.USD","BK4588","BK4585","LU0109394709.USD","LU1061106388.HKD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2494387996","title":"Exicure to Acquire GPCR Therapeutics' US Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2494387996","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494387996?lang=en_us&edition=fundamental","pubTime":"2024-12-27 16:51","pubTimestamp":1735289493,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) said late Thursday it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GPCR","BK4007","BK4599","XCUR"],"gpt_icon":0},{"id":"2494843517","title":"Exicure signs MOU with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2494843517","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494843517?lang=en_us&edition=fundamental","pubTime":"2024-12-27 09:25","pubTimestamp":1735262745,"startTime":"0","endTime":"0","summary":"The company states: “Exicure (XCUR) has announced the signing of a Memorandum of Understanding, MOU, with GPCR Therapeutics on December 24, 2024, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4599","BK4139","GPCR","XCUR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"GPCR","fiscalQuarterEnding":"2025/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1746417600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-05-09","current":-12.551909,"percent":0.904587,"low":-50.180001,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"high":-6.622278,"avg":-21.437807,"sd":7.904665,"marketCap":1537935156},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156}],"updateTime":1747094137666}}}